Navigation Links
Approximately One-Third of MS Patients Experiencing Relapses Do Not Adequately Respond to Traditional Corticosteroid Therapy, According to New Data Presented at the 5th Joint Congress of the European and Americas Committees for Treatment and Researc
Date:10/21/2011

or markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes
2. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
3. PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
4. Unilife COO Makes Open Market Purchase of Approximately $250,000 in Companys Publicly Traded Shares
5. Accuray to Acquire TomoTherapy for Approximately $277 Million in Cash and Stock
6. Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
7. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
8. HA&W Obtains Approximately $2 M in Credits and Cash Grants for Clients Through the Therapeutic Discovery Project Program
9. The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
10. Consumer Reports Flu Poll: Approximately Three Out of 10 Health Care Workers Living in a Bubble, Not Getting Flu Vaccine
11. The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Amgen (NASDAQ: AMGN ... Authorization Application (MAA) to the European Medicines Agency ... AMG 416) for the treatment of secondary hyperparathyroidism ... (CKD) on hemodialysis therapy. If approved, etelcalcetide will ... administered intravenously. Etelcalcetide is a novel ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ... the "An Introduction to Medical Device Software: ... 2015)" conference to their offering. ... to the regulations and requirements that apply to ... interactive, using real life examples and state-of- the-art ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has announced ... (London, UK - November 16-17, 2015)" conference to ... modules concerning Pharmacovigilance are a major departure in terms ... Europe . The intention of the course is ... how they overlap and fit together and what Companies ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... 8 Novavax, Inc. (Nasdaq: NVAX ) ... Driscoll, Chief Financial Officer of Novavax will be presenting ... place on Friday, September 17, 2010 at 10:20am local ... Driscoll will provide a company overview, outline its competitive ...
... (Nasdaq: TRBN ) today announced that the ... early termination of the waiting period under the Hart-Scott-Rodino ... with respect to the planned acquisition of Trubion by ... on Aug. 12, 2010. Accordingly, the requirement under the ...
Cached Medicine Technology:Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 2Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 3Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period 4
(Date:9/3/2015)... ... September 03, 2015 , ... The partnership will leverage ... technical support services to promote LodonalTM in Nigeria. The distribution will become effective, ... and safety of the product. , Managing Director, Fidson Healthcare Plc, Dr Fidelis ...
(Date:9/2/2015)... ... 03, 2015 , ... Leah Binder, MA, MGA, president and ... in healthcare, will offer the keynote address at the upcoming meeting of the ... Palm Harbor, Florida, at the Innisbrook Resort and Golf Club. For an agenda ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, ... America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and others ... that process led the magazine to tap the National League for Nursing’s outspoken ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... (WFS), cosponsored by the Military Officers Association of America (MOAA) and Wounded ... Nation's Military: Caring For Our Own,” expert panelists will lead interactive discussions ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Based in ... their fleet of truly superb luxury vehicles based on which of the latest and ... announce the latest step forward in pursuit of this goal: a 2015 Rolls ...
Breaking Medicine News(10 mins):Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2
... , , Patient-Based Record ... , MADISON, N.J., July 20 MedPlus, the ... DGX ), today announced that NYCLIX is now sharing ... New York City using the company,s Centergy(TM) suite of ...
... , SEOUL, South Korea, July 20 ... to announce that its wholly owned subsidiary, VASKA, a ... institutional, and consumer markets, has successfully turned the first major commercial ... Royal Laundry of South San Francisco is the largest ...
... , , ... campaign in support of bipartisan health care reform. , ... Plans (AHIP), "Illness", calls for fixing health care to make sure all Americans ... , "Illness doesn,t care where you live. . .or if ...
... , , , ... Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ -- Women today have a number ... of their families. Banking stem cells found in menstrual blood is one way ... injuries. Menstrual blood has been shown to contain self-renewing stem cells that may ...
... Calif., July 20 SynergEyes, Inc., the high Dk ... lens design for keratoconus patients. ClearKone(TM) is a revolutionary ... of the hybrid platform, providing superior visual acuity, centration, ... to vault the predominant irregularities of the keratoconic cornea, ...
... , , BRIDGEWATER, ... pooled results from two Phase 3 studies (DUET-1 and ... non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) ... copies/mL) while taking INTELENCE(TM) (etravirine) tablets plus background regimen ...
Cached Medicine News:Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 2Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 3Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Health Plans Return to Airwaves in Support of Bipartisan Reform 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 3Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 4Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 5Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 2Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 4Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 5Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 6
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... a critical component of pain relief, functional ... Lumbosacral Bracing System™ offers the practitioner multiple ... of immobilization, unparalled comfort, and the ability ... even if they gain or lose weight. ...
... Aspen® Cervical Collars were designed to optimize ... better patient outcomes. The structure of the ... restriction without producing painful pressure points that ... patient compliance. For the ultimate in comfort, ...
... This comfortable pre-fabricated orthosis is designed ... distal third humeral diaphyseal fractures. The ... circumferential soft tissue compression for optimal ... range-of- motion of both shoulder and ...
Medicine Products: